Invex Therapeutics' Exenatide Shows Promise in Alzheimer's Disease Model
IXC (IXC) Share Update December 2024 Sunday 15th
Invex Therapeutics Announces Promising Results for Exenatide in Alzheimer's Disease Model
Invex Therapeutics Limited (ASX: IXC) has revealed promising results from their collaboration with Tessara Therapeutics, showing that Exenatide significantly improves neuronal cell survival in a 3D human brain model of Alzheimer's Disease.
Instant Summary:
- Exenatide increased cell viability by 24% under oxidative stress conditions.
- A 45% increase in cell viability was observed under ferroptosis conditions.
- Exenatide was well tolerated across all tested doses.
- Data supports potential protective effects of GLP-1 receptor agonists against Alzheimer's dementia.
Breakthrough Findings
Invex Therapeutics Limited has announced significant findings from their collaboration with Tessara Therapeutics, utilizing the ADBrain™ platform. This 3D human brain model mimics the neurodegeneration seen in Alzheimer's Disease (AD). The study focused on Exenatide, a GLP-1 receptor agonist, and its effects on neuronal cell survival under conditions that replicate AD pathology.
Exenatide demonstrated a 24% increase in cell viability when exposed to oxidative stress conditions, which are common in AD patients. This was achieved using a low dose of Exenatide (0.1 μM) in the presence of hydrogen peroxide, a known inducer of oxidative stress.
Ferroptosis and Neuroprotection
Further tests showed a 45% increase in cell viability at a moderate dose of Exenatide (10 μM) under conditions of ferroptosis, a distinct pathway of cell death associated with AD. This suggests that Exenatide may protect neuronal cells from this form of cell death, which is triggered by reactive oxygen species and iron-dependent lipid peroxides.
The study's results are consistent with emerging clinical evidence that GLP-1 receptor agonists, like Exenatide, may offer neuroprotective benefits in AD, a market valued at USD 17 billion in 2023.
Future Implications
Invex plans to further explore Exenatide's mechanism of action in AD and its potential effects on other neurodegenerative diseases. This research could open new avenues for the treatment of conditions such as traumatic brain injury and Parkinson's Disease.
The promising results from this study could positively influence Invex Therapeutics' stock, as investors may view the potential application of Exenatide in Alzheimer's Disease as a significant opportunity. The broader market for AD treatments is substantial, and successful development could position Invex as a key player in this space.
Investor Reaction:
Analysts are likely to view this announcement as a positive development for Invex Therapeutics. The potential for Exenatide to be repurposed for Alzheimer's Disease could attract interest from investors looking for innovative solutions in the biopharmaceutical sector.
Conclusion:
Investors should keep an eye on Invex Therapeutics' future developments and collaborations as they continue to explore Exenatide's potential in treating Alzheimer's Disease and other neurological conditions. The company’s strategic moves in this area could significantly impact its market position.